Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IDPH--Positive preliminary results for pivotal trial of ID -- Ignore unavailable to you. Want to Upgrade?

To: Roader who wrote (1386)	12/3/1997 9:01:00 PM
From: aknahow	Respond to of 1762

Respoanse by Rastetter, Chairman, Pres, & CEO of Idec Pharm to Nov 25 article re Rituxan & Bexxar. In Investors Business Daily 3 Dec. page A32. Very well done, conclusion was, .."for many reasons, comparing Rituxan and any radioimmunotherapy is like comparing an apple and an orange." Letter goe into all the interesting details of why. Don't forget if any of you on this thread find out the percent paid to Xoma as a royalty please post this info. Was pleased to note start of sales in Europe.

To: Roader who wrote (1386)	12/3/1997 9:48:00 PM
From: Roger Cranwill	Read Replies (1) \| Respond to of 1762

It appears to me the announcement of the new arthritis drug being compared to CE9.1 implies the end of development of 9.1-anybody else read that into it? Roger IDEC (IDPH.O) antibody trial shows positive result SAN DIEGO, Dec 3 (Reuters) - IDEC Pharmaceuticals Corp said Wednesday said that a Phase I trial of a second-generation antibody it is developing for the treatment of rheumatoid arthritis showed several positive results. It said that trial on the product, Primatized anti-CD4 antibody IDEC-151/SB-217969, showed no depletion in CD4 cells, no infusion-related adverse events and longer coating action when administered at high doses compared to the first generation antibody, IDEC-CE9.1/SB-210396.